Cheap Broker Fees
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
GlaxoSmithKline plc is a drug manufacturers-general business based in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. GlaxoSmithKline employs 94,066 staff and has a trailing 12-month revenue of around USD$32.9 billion.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, GlaxoSmithKline's stock price has had significant negative movement.
Its last market close was $38.65, which is 10.28% down on its pre-crash value of $43.08 and 22.97% up on the lowest point reached during the March crash when the stocks fell as low as $31.43.
If you had bought $1,000 worth of GlaxoSmithKline stocks at the start of February 2020, those stocks would have been worth $681.59 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $827.11.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$38.65|
|52-week range||$31.42 - $42.14|
|50-day moving average||$39.36|
|200-day moving average||$39.19|
|Wall St. target price||$47.88|
|Dividend yield||$0.8 (2.07%)|
|Earnings per share (TTM)||$2.37|
|1 week (2021-10-12)||0.03%|
|1 month (2021-09-17)||-0.72%|
|3 months (2021-07-19)||-1.65%|
|6 months (2021-04-19)||1.76%|
|1 year (2020-10-19)||6.83%|
|2 years (2019-10-18)||-9.12%|
|3 years (2018-10-19)||40.87|
|5 years (2016-10-19)||41.49|
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, GlaxoSmithKline shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.3558. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.7 billion.
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$32.9 billion|
|Operating margin TTM||24.85%|
|Gross profit TTM||$23.2 billion|
|Return on assets TTM||6.32%|
|Return on equity TTM||24.29%|
|Market capitalisation||$98.1 billion|
TTM: trailing 12 months
There are currently 17.6 million GlaxoSmithKline shares held short by investors – that's known as GlaxoSmithKline's "short interest". This figure is 6.9% up from 16.4 million last month.
There are a few different ways that this level of interest in shorting GlaxoSmithKline shares can be evaluated.
GlaxoSmithKline's "short interest ratio" (SIR) is the quantity of GlaxoSmithKline shares currently shorted divided by the average quantity of GlaxoSmithKline shares traded daily (recently around 3.5 million). GlaxoSmithKline's SIR currently stands at 5.01. In other words for every 100,000 GlaxoSmithKline shares traded daily on the market, roughly 5010 shares are currently held short.
However GlaxoSmithKline's short interest can also be evaluated against the total number of GlaxoSmithKline shares, or, against the total number of tradable GlaxoSmithKline shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GlaxoSmithKline's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 GlaxoSmithKline shares in existence, roughly 10 shares are currently held short) or 0.0072% of the tradable shares (for every 100,000 tradable GlaxoSmithKline shares, roughly 7 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against GlaxoSmithKline.
Dividend payout ratio: 73.51% of net profits
Recently GlaxoSmithKline has paid out, on average, around 73.51% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.66% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 5.66% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.8 per share.
GlaxoSmithKline's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
GlaxoSmithKline's most recent dividend payout was on 6 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 18 August 2021 (the "ex-dividend date").
GlaxoSmithKline's shares were split on a 2:1 basis on 11 November 1991. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $31.4205 up to $42.1433. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.3928. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc. ; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.